Answers are grounded in this paper and cite their sources.
Qualitative case study reveals the roles of entrepreneurial identities and regulatory engagement in scaling health innovations.
This paper explores the transformation of Oculis, an Icelandic biotech company, from an academic research initiative into a publicly listed pharmaceutical firm on NASDAQ. Drawing on four in-depth interviews with the company’s scientific founders, an early-stage investor, and a senior executive, the study examines how health innovations are scaled through a deliberate interplay of identity transformation, strategic financing, regulatory engagement, and global team building. Using a qualitative case study approach, the paper identifies four central themes: 1 the shift from academic to entrepreneurial identities; 2 the use of phased investment and strategic partnerships to support growth; 3 regulatory navigation, especially engagement with the U.S. FDA, as a tool for institutional legitimacy; and 4 the development of a decentralized, cross-cultural leadership team. Situated within the literature on health care entrepreneurship, academic spin-offs, and institutional theory, this case contributes new insights into how science-based ventures can achieve credibility and scale in highly regulated, global markets. The findings underscore the importance of hybrid leadership, legitimacy-building narratives, and cross-sector collaboration in successfully commercializing scientific research.
No takes yet. Share an insight, caveat, or question.
Sigurjnsson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: